Analysis of Medicare Prescription Drug Plans in 2011 and Key Trends Since 2006
This report presents findings from an analysis of the Medicare Part D marketplace in 2011 and changes in drug coverage and costs since 2006.
View the Latest: Medicare Part D
Filter
-
-
Medicare Part D: A First Look at Prescription Drug Plans in 2017
Issue BriefThis issue brief provides an overview of the 2017 Medicare Part D stand-alone prescription drug plan marketplace, based on analysis of data from the Centers for Medicare & Medicaid Services. The brief focuses on data for 2017 and changes over time in plan availability, premiums, benefit design, cost sharing, and low-income subsidy plan availability.
-
Medicare Drug Plan Enrollees Would Face an Average 9 Percent Premium Increase Unless They Switch Plans During Open Enrollment, New Analysis Finds
News ReleaseCurrent enrollees in stand-alone Medicare Part D plans are projected to face an average 9 percent increase in premiums if they remain in their current plan for 2017, according to an analysis released today by the Kaiser Family Foundation. During Medicare’s 2017 open enrollment period, which runs from Oct. 15 through Dec.
-
Medicare Advantage 2024 Spotlight: First Look
Issue BriefFor 2024, the average Medicare beneficiary has access to 43 Medicare Advantage plans and can choose from plans offered by 8 firms. Among the majority of Medicare Advantage plans that cover prescription drugs, 66 percent will charge no premium in addition to the monthly Medicare Part B premium. As in previous years, the vast majority of Medicare Advantage plans will offer supplemental benefits, including fitness, dental, vision, and hearing benefits.
-
The New Help for Medicare Beneficiaries with High Drug Costs That Few Seem to Know About
Policy WatchThis policy watch highlights a change coming to the Medicare Part D drug benefit that will cap Part D enrollees' out-of-pocket drug costs, beginning in 2024, resulting in savings of thousands of dollars for high-cost drugs - a change that recent KFF tracking poll results show few older adults know about.
-
A Small Number of Drugs Account for a Large Share of Medicare Part D Spending
Issue BriefThe Inflation Reduction Act requires the federal government to negotiate the price of certain high-spending drugs covered by Medicare. This analysis provides context for understanding the potential impact of negotiating prices for a limited number of Medicare-covered drugs by identifying the 10 top-selling Part D drugs in 2021, measuring the share of total Part D drug spending accounted for by top-selling drugs that year, and examining changes in spending and use of these drugs since 2018.
-
New Weight Loss Drugs Raise Issues of Coverage, Cost, Access and Equity
Event Date:EventNew weight loss drugs, such as Novo Nordisk’s Ozempic and Wegovy (semaglutide) and Eli Lilly’s Mounjaro (tirzepatide), could be transformative for people who struggle with obesity and obesity-related medical conditions, but there are major questions to consider related to insurance coverage, the cost of the drugs, and who has access. On August 4, three experts joined Larry Levitt, executive vice president for health policy at KFF, for a 45-minute “Health Wonk Shop” discussion about the questions surrounding what a new generation of weight loss drugs means for patients and payers.
-
Gross Medicare Spending on Ozempic and Other GLP-1s Is Already Skyrocketing – Even Though Medicare Cannot Cover The Drugs for Weight Loss
News ReleaseA KFF analysis shows that gross total Medicare spending on Ozempic and other similar drugs has increased dramatically in recent years – even though Medicare is explicitly prohibited by law from covering the drugs for obesity. That’s because Medicare now covers the drugs, known as GLP-1s, for other medically accepted indications, including to treat diabetes.
-
People with Medicare Will Face Higher Costs for Some Orphan Drugs Due to Changes in the New Tax and Budget Law
Issue BriefThis brief analyzes changes in the new tax and budget reconciliation law that modify which drugs will be selected for Medicare drug price negotiation, which will lead to higher Medicare spending and higher costs for beneficiaries who take these medications.
-
Summary/Chartpack: National Survey of Pharmacists and National Survey of Physicians, Findings on Medicare Part D
Poll FindingThis document highlights key data from separate surveys of pharmacists and physicians related to the new Medicare drug benefit. Chartpack (.